Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a HER2-positive or HER2-expressing solid tumour (a tumour that has spread or cannot be surgically removed) that has not responded to standard treatment, cannot be tolerated with standard treatment, or for which no standard treatment exists. (Note: one specific group in the trial requires HER2-negative tumours — confirm with trial site.)
• People who have at least one tumour that can be measured on a scan, using standard measurement guidelines.
• People who are willing and able to provide signed consent to participate.
• People who have a general health score of 0 or 1 on the ECOG scale, meaning they are fully active or able to carry out light work (confirm with trial site).
• People whose heart is pumping at 50% or more of its normal capacity, as measured by a heart scan (echocardiogram or MUGA scan).
• People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements (confirm with trial site for specific values).
• People who can provide existing HER2 test results, a previously removed tumour sample, or who are willing to have a new tumour biopsy taken for HER2 testing.
• People with a life expectancy of at least 3 months.

For one specific group in the trial (Part 2, Expansion Group 9), additional criteria apply:

• People who have been diagnosed with advanced or metastatic endometrial cancer (including certain subtypes: uterine carcinosarcoma or uterine serous papillary carcinoma), whose disease has progressed after receiving at least one prior treatment including platinum-based chemotherapy and an immune checkpoint inhibitor, but who have had no more than three prior lines of treatment for advanced or metastatic disease. (Note: hormone therapy does not count as a qualifying treatment line.)

Who may not be able to join:

• People who have a history of significant heart failure (classified as moderate to severe) or serious heart rhythm problems that required treatment.
• People who had a heart attack or unstable chest pain within the 6 months before the trial start date.
• People whose heart's electrical activity shows a prolonged interval on an ECG (above 450 ms for males or 470 ms for females) (confirm with trial site).
• People who have a history of clinically significant lung disease.
• People who have an active, uncontrolled infection currently requiring intravenous antibiotics, antiviral, or antifungal treatment.
• People who have HIV with AIDS-related illness, or who have an active hepatitis infection.
• People who have brain metastases (cancer that has spread to the brain) that are currently causing symptoms or are considered active.
• People who still have side effects from previous cancer treatments that have not recovered to a mild level or returned to their baseline health status.
• People who are known to have a severe allergy or sensitivity to the trial drug or any of its ingredients.
• People (in the expansion part of the trial only) who have had more than one type of cancer within the past 3 years — unless the additional cancer was a non-melanoma skin cancer that was fully removed, a cancer that was cured with treatment, or a contralateral breast cancer.

Important: Always verify eligibility with the trial site directly before applying.